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Objective: Ischemic preconditioning is now established as an effective means of 
reducing infarct size. However, it remains uncertain whether preconditioning 
can improve the myocardial protection afforded by cardioplegia. The present 
study was designed to address this issue. Methods: After the institution of 
cardiopulmonary b pass, 10 patients were preconditioned with 3 minutes 
of aortic crossclamping followed by 2 minutes of reperfusion before the onset 
of retrograde continuous warm cardioplegic arrest. Ten case-matched patients 
served as controls. Three blood samples were drawn simultaneously from the 
radial artery and the coronary sinus before bypass, at the end of the 5-minute 
preconditioning protocol or after 5 minutes of bypass in control patients, and 
at the end of cardioplegic arrest. These samples were assayed for creatine 
kinase MB isoenzyme and lactate. Right atrial biopsy specimens taken at the 
same time points were processed by Northern blotting for the expression of 
messenger ribonucleic acid of both c-los and heat shock protein 70. Results: At 
the end of arrest, the release of creatine kinase MB from the myocardium was 
markedly greater in preconditioned patients than in the controls. The 
transmyocardial l ctate gradient was shifted toward production i  the precon- 
ditioned group (+0.22 +- 0.13 mmol/L) and toward extraction in the control 
group (-0.06 -- 0.21 mmol/L). Molecular biology data did not suggest a 
protective ffect of preconditioning. There were no clinical adverse events 
related to preconditioning. Conclusions: Preconditioning does not enhance 
cardioplegic protection and might even be deleterious. These results do not 
dismiss its use in cardiac operations. They rather emphasize the need for 
identifying pharmacologic mediators that could safely and effectively duplicate 
the cardioprotective effects of ischemic preconditioning. (J Thorac Cardiovasc 
Surg 1996;112:1378-86) 
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schemic preconditioning has been a powerful 
means of reducing infarct size in several animal 
models of myocardial regional ischemia. 1 In the 
setting of global ischemia, some studies have also 
reported that preconditioning improved functional 
recovery after hypothermic 2 or cardioplegic 3° 4 ar- 
rest. These observations have raised the possibil- 
ity that preconditioning might enhance the effi- 
cacy of current methods of intraoperative 
myocardial protection. This prospect is appealing 
because cardiac surgery (along with percutaneous 
transluminal coronary angioplasty) offers the 
unique opportunity of planning the onset of aortic 
crossclamping and the attendant period of isch- 
emic arrest. This allows timely implementation of
the preconditioning stimulus and, therefore, 
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Fig. 1. Experimental protocol. 
makes this form of protection particularly well 
suited for an intraoperative use. 
At first glance, this hypothesis seems upported by 
the study of Alkhulaifi and coworkers. 5'6 These 
authors subjected patients undergoing coronary ar- 
tery bypass grafting to a preconditioning regimen 
consisting of two 3-minute cycles of aortic cross- 
clamping followed by 2 minutes of reperfusion be- 
fore a 10-minute period of normothermic ventricu- 
lar fibrillation. The major finding of this study was 
that at the end of the ischemic interval, myocardial 
tissue levels of adenosine triphosphate (ATP) were 
higher in preconditioned patients than in the control 
patients. However, whether this approach is relevant 
to cardioplegia-based preservation techniques re- 
mains unresolved. The present study was designed 
to address this issue. Along with standard biochem- 
ical and enzymatic indices, end points included 
measurements of myocardial levels of the protoon- 
cogene c-los and of the heat shock protein (HSP) 70 
messenger ribonucleic acids (mRNAs), because the 
expression of these two proteins is synergistically 
up-regulated by ischemia as part of the heart's 
genetic adaptive response to environmental stress. 
Methods 
Patients. Twenty patients undergoing isolated coronary 
artery bypass operations were prospectively entered into 
this study, which was approved by our institutional human 
experimentation committee. Anesthesia was uniform in 
all cases and consisted of a standardized combination of 
fentanyl citrate, flunitrazepam, and pancuronium bro- 
mide. Cardiopulmonary bypass (CPB) was established 
with a crystalloid prime between the ascending aorta and 
the two venae cavae. CPB equipment consisted of a roller 
pump, a membrane oxygenator, and an in-line arterial 
filter. Left ventricular venting was accomplished in all 
patients through the right superior pulmonary vein. CPB 
was run at a flow rate of 2.2 L/min per square meter, and 
isoflurane (1%) or phenylephrine hydrochloride was used 
whenever equired to maintain systemic pressures be- 
tween 50 and 70 mm Hg. The core temperature, as 
assessed by a nasopharyngeal probe, was allowed to drift 
and fell to a nadir of 31 ° to 32 ° C. Myocardial protection 
was achieved with continuous retrograde blood cardiople- 
gia maintained at the same temperature asthe systemic 
perfusate and delivered according to our previously de- 
scribed "minicardioplegia" infusion technique. 7 Adminis- 
tration of heparin before cannulation and its subsequent 
postbypass reversal by protamine sulfate were accom- 
plished in a standard fashion. 
Patients were randomized into one of two groups. After 
the onset of full-flow CPB with effective left ventricular 
decompression, patients assigned to the preconditioning 
protocol underwent a single 3-minute period of aortic 
crossclamping followed by 2 minutes of reperfusion before 
the onset of cardioplegic arrest. In control patients, a 
period of CPB of similar duration and under the same 
conditions of flow and left ventricular venting was insti- 
tuted before the application of the aortic crossclamp (Fig. 
1). Prearrest pacing was not used in either group. End points. Blood samples were simultaneously drawn 
from the radial artery and the coronary sinus catheter 
before the institution of CPB, at the end of the 5-minute 
preconditioning sequence (transient aortic occlusion/ 
reperfusion) or after an equivalent period of CPB in 
control patients, and at the end of cardioplegic arrest, 
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Fig. 2. CK-MB isoenzyme release during the course of 
the protocol in the preconditioning (PC) and control 
groups. 
immediately before the removal of the aortic crossclamp. 
Samples were assayed for lactate by reflectance spectro- 
photometry (Eastman Kodak Company, Rochester, N.Y.) 
and for the MB isoenzyme of creatine kinase (CK-MB) by 
an immunometric technique (Ciba Corning, Medfield, 
Mass.). 
Three sequential biopsies of the right atrial free wall 
close to the appendage were performed, at the same time 
intervals as the blood samples. The specimens were 
immediately frozen in liquid nitrogen and stored at 
-70 ° C. Total RNA was first extracted according to the 
technique described by Chomczynski and Sacchi. 7a North- 
ern blot analysis was then performed using 25 to 50 ~g 
total RNA per lane. Blots were successfully hybridized 
with probes specific for c-los, HSP 70, and 18S rRNA. To 
this end, a 1.06 Kb Pst 1 fragment of a v-fos DNA cloned 
by Curran and associates TM and an EcoRI-BamHI frag- 
ment of genomic HSP 70 DNA cloned by Zakeri and 
colleagues 7c were labeled with (a-32P)deoxycytidine 
triphosphate (3000 Ci/mmol) using a random primer 
labeling reaction (Amersham Rediprime labeling system 
RPN 1633; Amersham Corp., Arlington Heights, Ill.). The 
18S probe was a 24-mer oligonucleotide specific to the 
ribosomal 18S RNA. This probe was synthesized at the 
Institut Pasteur (Paris, France) and was 5'-end labeled 
using T4 polynucleotide kinase and (3,-32P)ATP (6000 
Ci/mmol). Hybridization with labeledfos or HSP 70 DNA 
was performed for 12 to 16 hours at 42°C in 50% 
formamide, 5× saline-sodium citrate buffer, 0.1% 
(weight/volume) sodium dodecylsulfate, 5× Denhardt's 
solution, 250 gm/ml of sonicated herring sperm DNA, and 
50 mmol/L NaH2PO 4 at pH 6.5. A hybridization solution 
of the same composition, but without formamide, was 
used for the hybridization with the 18S rDNA probe. 
Membranes hybridized with the los and HSP 70 probes 
were washed twice for 10 minutes in 2× saline-sodium 
Table I. Patient data 
Control group Preconditioned 
Variable (n = 10) group (n = 10) 
A (yr) 63 _+ 4 68 _+ 3 
Sex ratio (M/F) 7/3 7/3 
Unstable angina 6 5 
LV ejection fraction (%) 55 -+ 4 55 +_ 3 
CPB time (min) 107 +- 7 110 _+ 8 
CPB temperature (°C) 32.1 _+ 0.3 31.7 _+ 0.4 
Aortic crossclamping (rain) 72 _+ 6 64 _+ 5 
Cardioplegia off (min) 3 _+ 1 4 ± 2 
Spontaneous defibrillation 7 10 
LV, Left ventricular; CPB, cardiopulmonary b pass. As applicable, data 
are shown as number of patients or mean -+ the standard error of the 
mean. 
citrate buffer, 0.1% (weight/volume) sodium dodecylsul- 
fate at room temperature, and twice in 2× saline-sodium 
citrate buffer, 0.1% (weight/volume) sodium dodecylsul- 
fate at 50 ° C for 15 minutes. After hybridization with the 
18S rDNA probe, membranes were washed three times at 
room temperature in 3 × saline-sodium citrate buffer for 
10 minutes. To quantify hybridization signals, the blots 
were exposed (1 to 3 hours) to a BAS 1000-imaging plate 
(Bioimaging analyzer, Fujix, Tokyo, Japan) in an autora- 
diographic assette. The images obtained after scanning 
were transformed to numerical data by means of the 
analysis function of MacBAS software (Fujix). The densi- 
tometric values corresponding to the c-fos or HSP 70 
hybridization signals were normalized for the 18S rRNA 
signal, and results of c-los and HSP 70 mRNA expression 
are presented as the percentage of the signal given by rat 
cardiac RNA sample extracted from a cycloheximide- 
treated animal s used as an internal standard. 
Statistical analysis. Comparison between the two 
groups was performed by two-way analysis of variance 
with repeated measures and unpaired two-tailed t tests. 
Paired two-tailed t tests were used for comparing data 
within each group. Statistical significance was set at the 
0.05 level. Results are given as mean plus or minus the 
standard error of the mean. 
Results 
The major preoperative and intraoperative vari- 
ables were similar in the two groups (Table I). Like- 
wise, there was no significant difference between 
groups with regard to pre-CPB arterial and coronary 
sinus values for lactate and CK-MB. There was also no 
difference in c-los and HSP 70 mRNA expression, 
assessed by the first pre-CPB biopsy, between precon- 
ditioned patients and those of the control group. 
At the end of the crossclamp eriod, the release 
of CK-MB from the coronary sinus was greater in 
preconditioned patients than in control patients 
(Fig. 2). As assessed by repeated-measures analysis 
of variance, the difference between groups almost 
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Fig. 3. Lactate metabolism data during the course of the protocol in preconditioning (PC) and control 
groups. Each group consisted of 10 patients. Results are given as means - standard error of the mean. 
Table II. Quantitative xpression of c-los and HSP 70 mRNA in the preconditioned and control groups 
c-fos (% I.S.) HSP 70 (% LS.) 
Group 
End of PC~5 End of PC/5 
Time points Pre-CPB min of CPB End arrest Pre-CPB rain of CPB End arrest 
Control  (n = 7) 16 _+ 6 66 _+ 16" 93 _+ 22* 118 - 35 144 _+ 46 148 + 49 
PC (n = 7) 26 _+ 10 91 _+ 22* 131 _+ 24* 130 -+ 32 148 _+ 35 203 + 47 
PC, Preconditioning. Results are expressed as the percentage of the signal given by rat cardiac RNA sample xtracted from a cycloheximide-treated animal 
used as an internal standard (I.S.). 
*p < 0.05 versus Pre-CPB. 
reached the level of statistical significance (p = 
0.05). Whereas control patients extracted lactate at 
the end of the crossclamp period, consistent with the 
use of aerobic ardioplegia, lactate metabolism was 
shifted toward production in the preconditioned 
group (Fig. 3). This pattern was present at the end 
of the 2-minute period of intervening reperfusion 
that followed the 3-minute ischemic preconditioning 
challenge and remained unchanged thereafter. 
Levels of c-los significantly increased after the 
preconditioning period and the 5-minute CPB 
period (Table II), and this increase was similar in 
the two groups. The c-fos mRNA levels were 
significantly higher in atrial tissue excised imme- 
diately after preconditioning and at the end of 
cardioplegic arrest than in the pre-CPB atrial 
sample, but this increase was of similar magnitude 
in the two groups. In contrast o c-fos, HSP 70 
mRNA levels measured at the end of the cross- 
clamp period were unchanged from baseline val- 
ues in both groups (Table II). A representative 
Northern blot of c-los and HSP 70 in control and 
preconditioned patients at the three time intervals 
is shown in Fig. 4. 
Postoperative r coveries were uneventful in the 
two groups. There were no adverse clinical events 
related to preconditioning. 
Discussion 
Interpretation of results. The major finding of 
this study is that a single cycle of ischemic precon- 
ditioning does not improve the cardioprotective 
effects of continuous retrograde warm blood cardio- 
plegia, as assessed by standard biochemical and 
enzymatic measurements. There is even some evi- 
dence that as short a period of aortic crossclamping 
1382 Perrault et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
November 1996 
Ch Contro l  PC PC 
HSPT0 
mRNA 
_ c-fo$ 
mRNA 
_ 18S RNA 
Fig. 4. Representative Northern blot of c-los and HSP 70 mRNAs in one control and two preconditioned 
patients before CPB (1), after the preconditioning protocol or 5 minutes of CPB (2), and at the end of the 
cardioplegic arrest period (3). The Ch lane represents the signal given by a rat cardiac RNA sample 
extracted from a cycloheximide-treated animal used as an internal standard. The densitometric values 
corresponding to the c-los or HSP 70 hybridization signals were normalized for the 18S rRNA signal. 
as 3 minutes before the protracted period of car- 
dioplegic arrest could have detrimental effects re- 
flected by a greater release of CK-MB isoenzymes in 
the coronary sinus effluent and a shift of lactate 
metabolism toward production at the end of car- 
dioplegic arrest. Lactate production persisted in the 
preconditioned group even though one would have 
anticipated the greatest changes in lactate xtraction 
immediately after r perfusion after the brief pre- 
conditioning ischemic interval. We have no clear 
explanation for this observation. It is possible that 
the ischemic stress induced by preconditioning was 
of such magnitude that once cardioplegic arrest was 
superimposed after only 3 minutes of reperfusion, it 
could not be fully reverted espite continuous de- 
livery of blood cardioplegic solution. The occur- 
rence of such ischemic damage persisting through- 
out the period of arrest is indeed supported by the 
markedly greater CK-MB values found in the pre- 
conditioned group at the end of arrest. Alterna- 
tively, the wide scattering in the lactate data may 
have shifted the lactate gradient toward extraction 
in the control group and toward production in the 
preconditioned group, but the fact that the group 
means were not significantly different (p = 0.3) 
should lead to caution in the interpretation of this 
finding. In addition, myocardial levels of the mRNA 
for the protooncogene c-los significantly increased 
throughout the crossclamping period. This increase 
could be expected inasmuch as this protooncogene 
is readily expressed in response to stressful stimuli. 
However, the intraoperative rise in c-los levels was 
of similar extent in the two groups, suggesting that 
the magnitude of stress induced by CPB and super- 
imposed cardioplegic arrest had not been reduced 
by the prearrest preconditioning regimen. Further- 
more, protooncogenes participate in the cellular 
response to stress by causing the transcriptional 
activation of genes that code for critical regulatory 
proteins. In this setting, c-los is involved in the 
"switch on" of the HSP 70 gene. This protein is 
up-regulated in response to a variety of stressful 
stimuli including heat, pressure, and volume over- 
load, myocardial stretch, hypoxia, and ischemia. The 
protective ffects of HSPs are mainly attributed to 
their ability to prevent abnormal protein-protein 
interactions and might account for the correlation 
between increased expression of myocardial HSP 70 
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and accelerated functional recovery of stunned myo- 
cardium. 9-11 In the present study, the patterns of 
changes in HSP 70 mRNA differed from those of 
c-los in that they did not increase significantly during 
the operation in either group, an observation con- 
sistent with that of McGrath and coworkers. ~2 
At least four hypotheses can be raised to explain 
this finding. First, it is possible that the HSP content 
of diseased myocardium is already so elevated that it 
cannot be up-regulated further by a preconditioning 
stimulus. This assumption is primarily based on the 
fact that high levels of HSP 72 inhibit the transcrip- 
tion factor equired for additional protein synthesis. 
Second, the last biopsy may have been performed 
too early to allow for the detection of a delayed 
increase in HSP 70 mRNA expression. However, 
this biopsy specimen was taken an average of 70 
minutes after the preconditioning stimulus, which is 
within the time span previously reported for observ- 
ing an increased expression of the mRNA coding for 
this protein. 13 A third possibility could be that the 
adaptive capacity to stress decreases with advancing 
age. 14 However, in the study of McGrath and asso- 
ciates, 12 the myocardial content of HSP 70 also 
failed to increase during the course of the operation 
in several young patients. Fourth, the duration of 
the preconditioning ischemic stimulus used in our 
study may have been too short o elicit an increase in 
HSP 70 mRNA, whereas the performance ofthe last 
biopsy before removal of the aortic crossclamp may 
have led to an underestimation of the accumulation 
of HSP 70 mRNA because the latter seems to 
involve a reperfusion-dependent component.15 
However, although adelayed increase in myocardial 
levels of HSP 70 in the preconditioned group cannot 
be excluded, the analysis of patient outcomes indi- 
cates that, if it occurred, this increase did not 
translate into a clinically detectable improvement in 
postoperative recovery. On the other hand, the 
preconditioning ischemia may have been severe 
enough to cause cellular damage reflected by 
CK-MB release from the myocardium, which is 
known to down-regulate HSP 70 mRNA transcrip- 
tion. Consequently, our observations do not favor a 
role for the preconditioning protocol used in this 
study in eliciting the specific component of endoge- 
nous protection presumably mediated by stress- 
inducible proteins. 
Preconditioning in the setting of cardiac surgery. 
Actually, the lack of additional protection provided 
by preconditioning in the present study is consistent 
with several well-established features of this adap- 
tive phenomenon. First, as previously stated, the 
major benefit of preconditioning is to reduce infarct 
size, and a large body of evidence confirms that the 
improvement in functional recovery seen in precon- 
ditioned hearts submitted to global ischemia is 
primarily due to a limitation of infarct size, not a 
reduction of stunning incurred by nonnecrotic myo- 
cardium. 16 This was well demonstrated in the study 
of Illes and associates, 3 in which the improvement in 
function found in preconditioned hearts after car- 
dioplegic arrest correlated with a reduced leakage of 
CK. This finding may limit the relevance of precon- 
ditioning to cardiac operations, because arly post- 
CPB pump failure is more commonly due to stun- 
ning than to overt infarction. Second, although the 
end-effectors of the intracellular signaling pathway 
elicited by the preconditioning stimulus are not yet 
fully characterized, it appears that a major mecha- 
nism whereby preconditioning exerts its cardiopro- 
tective effects is a slowing of the rate of ATP 
depletion during the protracted period of ischemia. 
This hypothesis has been challenged inexperimental 
situations of total no-flow ischemia in which precon- 
ditioning was unexpectedly found to accelerate the 
fall of ATP. 17 However, no-flow ischemia is not 
relevant o the clinical situation of aortic cross- 
clamping, because some residual myocardial f ow 
originating from noncoronary collateral vessels per- 
sists and the heart is perfused continuously with a 
normothermic blood cardioplegic solution. Thus it is 
conceivable that preconditioning may afford some 
protection when used, as in Alkhulaifi's tudy, 5 in 
conjunction with a technique such as normothermic 
ventricular fibrillation, which causes a drastic de- 
cline in myocardial levels of high-energy phos- 
phates. Preconditioning could also contribute to 
successful results in techniques using intermittent 
aortic crossclamping 18 because the first episode of 
warm ischemia could be equivalent to a precondi- 
tioning stimulus that limits cumulative deterioration 
of left ventricular function with subsequent ischemic 
intervals. 19 Conversely, the ATP-sparing effect of 
preconditioning may become redundant with that of 
cardioplegia. This hypothesis i supported by the 
observation that, in a rat model of normothermic 
global ischemia of short duration (35 minutes), 
ischemic preconditioning and cardioplegia have 
been shown to be equally effective, but without 
additive effects. 2° Similarly, Steenbergen and co- 
workers 21 have reported that preconditioning used 
in conjunction with magnesium arrest failed to 
improve protection beyond that provided by cardio- 
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plegia alone. It is noteworthy that magnesium is 
included in our cardioplegic formulation. The the- 
ory that any intervention that reduces myocardial 
oxygen consumption during the protracted period of 
ischemia may prevent he protective ffects of pre- 
conditioning from occurring is further supported by 
the recent observation that preservation of ATP 
levels seen in patients kept normothermic during 
ventricular fibrillation 5is lost when patients precon- 
ditioned in a similar fashion are cooled to 32 ° C. 22 
Indeed, the two situations in which preconditioning 
has been shown to provide better protection than 
hypothermia or cardioplegia alone are long ischemic 
times 2 and maldistribution of cardioplegic solution 
because of proximal coronary artery occlusion. 23 We 
suspect that, in these two settings, suboptimal myo- 
cardial preservation may have caused some degree 
of myocardial necrosis, thereby accounting for the 
benefits of preconditioning through its infarct size 
limiting effects. In the present study, aerobic perfu- 
sion was continuously maintained during cross- 
clamping periods of similar durations, while 
distribution of cardioplegic solution was optimized 
through the use of the retrograde route. These 
conditions may have left little room for precondi- 
tioning to "'compensate" for a suboptimal myocar- 
dial preservation, hence its inability to yield addi- 
tional cardioprotection. Our results lead us to be 
careful about speculating that intermittent warm 
blood cardioplegia could be beneficial, because pe- 
riods of no flow could, presumably, precondition the 
heart. This hypothesis is intellectually attractive 
because it tends to justify the use of a technique 
more directed at improving the surgeon's comfort 
during the operation than at meeting the energy 
requirement of the myocardium. There is. however, 
no sound experimental or clinical information cur- 
rently available to support his hypothesis. 
A third confounding factor could be the ability of 
CPB to elicit, by itself, some form of precondition- 
ing, perhaps through activation of adenosine and 
oz-adrenergic receptors. 24If such was the case, all 
our patients may have already been preconditioned 
by the brief CPB period preceding cardioplegic 
arrest, which could explain why a superimposed 
episode of ischemic preconditioning failed to pro- 
vide additional protection. 
Fourth, Bukhari and associates 25have recently 
reported that aprotinin could negate the cardio- 
protective ffects of preconditioning. This factor, 
however, is unlikely to have skewed our results, 
because aprotinin administration was evenly dis- 
tributed in the two groups (three patients in each 
group). 
A last intriguing observation is that not only did 
our preconditioned patients not show improved 
protection, but they even tended to have greater 
evidence of enzymatic and metabolic myocardial 
damage. We do not have a clear explanation for this 
finding. It is conceivable that the washout of aden- 
osine, believed to be a key trigger of the intracellular 
signaling pathway that ultimately leads to precondi- 
tioning,related cardioprotection by continuous blood 
cardioplegic perfusion, may have prevented it from 
exerting its expected benefits and resulted in the 
damaging effects of a prearrest period of global isch- 
emia. Additionally, the activation of ATP-dependent 
potassium channels, considered likely effectors of the 
signaling pathway elicited by preconditioning, 26 may 
have been attenuated by the hyperkalemic cardiople- 
gic solution used, thus limiting their cardioprotective 
effects. 1 This scenario, however, isunlikely in this study 
because the serum potassium concentrations resulting 
from our cardioplegia delivery technique are by far too 
low (6 to 7 mEq/L) to abolish the transsarcolemmal 
potassium electrochemical gradient. Overall, the neg- 
ative biochemical findings of this clinical study with 
ischemic preconditioning are consistent with the re- 
port by Bolting and coworkers, 27which found an 
episode of no-flow ischemia before cardioplegic arrest 
to cause some adverse ffects evidenced by an impair- 
ment of oxygen utilization efficiency and the absence 
of functional benefits during reperfusion. 
Methodologic limitations. At least two limita- 
tions have to be addressed. First, the precondition- 
ing protocol may have been inadequate. A 5-minute 
period (3 minutes of crossclamping followed by 2 
minutes of reperfusion) was chosen to fit clinically 
acceptable time constraints. Experimentally, such a 
timing has been shown to elicit cardioprotection 
and, on the basis of our enzymatic and metabolic 
data, we would now consider a longer period of 
ischemic preconditioning before cardioplegic arrest 
ethically questionable. A second concern relates to 
the study Of genetic markers. In addition to the 
previously discussed limitations inherent o the tim- 
ing of the sampling protocol, it could be argued that 
assessment of HSP 70 mRNA levels is not as 
relevant as measurement of the protein itself. Nev- 
ertheless, a good temporal correlation has previ- 
ously been reported between increases in levels of 
HSP 70 mRNA and those of the protein. 2s Alterna- 
tively, it is possible that right atrial tissue is not 
appropriate for detecting changes in stress proteins, 
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because these proteins, preferentially expressed in 
ischemic areas, 1° may not be synthesized in great 
amounts in the right atrium, whose blood supply is 
not primarily dependent on coronary vessels and 
thus may not reflect adequately changes in ventric- 
ular stress proteins. 
Conclusion 
The present study leads us to advise caution about 
the clinical use of ischemic preconditioning before 
normothermic blood cardioplegic arrest. This con- 
clusion does not preclude a possible use for some 
form of pharmacologic preconditioning which, 
based on current knowledge, could primarily rely on 
activation of adenosine receptors or opening of 
ATP-sensitive potassium channels. 24'29 Whether 
pharmacologic preconditioning may be beneficial in 
clinical practice still remains to be established; how- 
ever, ischemic preconditioning byaortic crossclamp- 
ing should be avoided because of its potential 
detrimental effects. Perhaps minimally invasive off- 
pump coronary artery bypass operations 3° and on- 
pump revascularization without aortic crossclamp- 
ing will turn out to be appropriate elective 
indications for ischemic preconditioning. Indeed, 
the local isolation of the target blood vessels re- 
quired to perform the anastomosis on the beating 
heart best reproduces animal models of regional 
ischemia that have yielded the most convincing 
evidence of the cardioprotective effects of precon- 
ditioning. 
We acknowledge the help of Madame Roselyne Prioux 
in the preparation of the manuscript. 
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Discuss ion 
Dr. Steven F. Boiling (AnnArbor, Mich.). I am also part 
of a group that studies preconditioning. Without a doubt, 
it is a very vexing area, as to its application to cardiac 
surgery. 
I have a number of specific questions. Is your model 
actually a model of ischemic preconditioning? You used 
warm retrograde continuous cardioplegia nd have pub- 
lished on this method, your miniblood cardioplegia, in an 
effort to reduce ischemia. Might this not be just a model of 
ischemia followed by no ischemia, which is not precondi- 
tioning? You do not have histopathologic data, not nec- 
essary inasmuch as this is a study in patients, but you do 
not show whether this is a model of myocyte necrosis or 
stunning. 
Second, if this is preconditioning, did preconditioning 
occur? Perhaps there are other, better markers of precon- 
ditioning that could be followed as opposed to c-los and 
HSP. Protein kinase C isoforms are perhaps better indi- 
cators of the occurrence of preconditioning, especially the 
delta and epsilon isoforms. Third, why were right atrial 
biopsy specimens used? The correlation between right 
atrial myocyte changes and ventricular myocyte changes 
are not always the same. 
Last, I think the title is appropriate: We must use a 
word of caution. In this kind of study a beta error of 
statistics can occur. If preconditioning is not shown in this 
particular model, it does not mean that preconditioning 
does not exist. This is a small number of patients. With no 
difference in clinical or biochemical outcomes, we cannot 
assume that preconditioning does not exist because we do 
not see it. I again agree with the authors that there are 
probably more effective pharmacologic interventions that 
would allow us to use preconditioning in cardiac surgery. 
Dr. Perrault. First, we agree totally with your first 
comment. Initially we thought that perhaps we could 
improve the degree of ischemia or stunning that is some- 
times seen even after warm normothermic continuous 
retrograde cardioplegia. 
Looking at the lactate data on the control group, perhaps 
you are right that there seems to be very little ischemia 
occurring and then there is little room for preconditioning to 
improve the results. Obviously, because this study was per- 
formed in patients, histopathologic data were not easily 
available. We agree that we have not documented the 
presence of stunning after the procedure. The precondition- 
ing stimulus did, however, cause acute electrocardiographic 
changes in a number of patients, but we did not study global 
or localized myocardial dysfunction. Also, although contin- 
uous peffusion of normothermic blood cardioplegic solution 
is associated in the majority of cases with good results, 
stunning and myocardial infarction leading to post-CPB 
pump failure still does occur at times. There may be subsets 
of high-risk patients perhaps with long crossclamp times or 
inadequate delivery of cardioplegia who might benefit from 
enhancement of cardioplegic protection. It is for this reason 
that we undertook this initial study in patients with normal 
ventricular function to see if any benefits could be detected 
after the preconditioning challenge. There is also no evi- 
dence that preconditioning has occurred, and we believe 
after performing this study that normothermic blood cardio- 
plegia may not enable preconditioning to show any benefits. 
As for our choice of the markers c-los and HSP 70, 
obviously the study of the isoforms of protein kinase C 
would take our understanding of preconditioning in hu- 
man beings one step further, but it also depends on the 
locally available resources for molecular biology markers. 
I am sure that other studies will be conducted with those 
markers and will show either evidence of preconditioning 
or perhaps more relevant information. 
Right atrial biopsies were performed because the spec- 
imens were readily available near the cannulation site. We 
did not feel comfortable doing ventricular biopsies, and 
this was not acceptable to the ethical committee. In 
conclusion, we found that considering the good results 
obtained with normothermic cardioplegia, ischemic pre- 
conditioning, atleast with this specific protocol, could not 
improve the protection i  patients with normal ventricular 
function. 
